The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic agent for improving early symptoms of idiopathic Parkinson's disease. It appears to exert this action independently of its inhibition of monoamine oxidase B (MAO-B) and some of its metabolites are thought to contribute. Cytochrome P450 (CYP) activities are known to give rise to L-deprenyl metabolites that may affect the dopaminergic system. In order to clarify the interactions of L-deprenyl with these enzymes, C57BL mice were treated with L-deprenyl, ethanol, phenobarbital or beta-naphthoflavone to induce different CYP isozymes. After preincubation of L-deprenyl with liver microsomes from control or treated mice, the metabolites were analysed b...
L-Deprenyl, a monoamine oxidase (MAO)-B inhibitor, appears to slow down the progression of Parkinson...
This report describes experiments designed to determine whether(-)-deprenyl potentiates dopaminergic...
Utilizing behavioral, biochemical and electrophysiological meth-ods, central effects of the monoamin...
The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic ag...
The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic ag...
monoamine oxidase-B (MAO-B) inhibitor, l-deprenyl, is still used for treating Parkinson's patie...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
L-Deprenyl, a monoamine oxidase (MAO)-B inhibitor, appears to slow down the progression of Parkinson...
This report describes experiments designed to determine whether(-)-deprenyl potentiates dopaminergic...
Utilizing behavioral, biochemical and electrophysiological meth-ods, central effects of the monoamin...
The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic ag...
The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic ag...
monoamine oxidase-B (MAO-B) inhibitor, l-deprenyl, is still used for treating Parkinson's patie...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The aim of the present investigation was to characterize the cytochrome P450 (CYP)-dependent metabol...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
The selective monoamine oxidase-B (MAO-B) inhibitor, ldeprenyl, is still used for treating Parkinso...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
1. The aim was to clarify the kinetic and cytochrome P450 (CYP) enzymes involved in l-deprenyl metab...
L-Deprenyl, a monoamine oxidase (MAO)-B inhibitor, appears to slow down the progression of Parkinson...
This report describes experiments designed to determine whether(-)-deprenyl potentiates dopaminergic...
Utilizing behavioral, biochemical and electrophysiological meth-ods, central effects of the monoamin...